Latest From Biotech Now

BIO Investor Forum’s Impressive Program Lineup

BIO Investor Forum

This week, BIO announced the final program and speakers for the 14th Annual BIO Investor Forum, an international investor forum which explores investment trends and opportunities in life sciences.  The event focuses on early and mid-stage private as well as emerging public companies that are poised for growth in 2016. The event will take place October 20-21, 2015, at the Parc 55 in San Francisco, California. “This year’s BIO Investor Forum features a compelling and Read More >

Events  |  Leave a comment  |  Email This Post

Dr. Scott Gottlieb: A Clintonian Misdirection on Drug Prices

Hillary Clinton

Today’s Wall Street Journal contains an excellent op-ed by Dr. Scott Gottlieb, a physician and resident fellow at the American Enterprise Institute. Dr. Gottlieb takes aim at the recent proposal offered by the campaign of Secretary Hillary Clinton to aggressively regulate the price of innovative prescription medicines. BIO shared many of those concerns in our statement and a related blog post. Dr. Gottlieb notes, “It’s important to distinguish between new medicines that are priced at Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Why I packed my bag and headed to NASDA 2015 in Hawaii

Lorie Farrell

As the head wrangler and ringleader for Hawaii Farmers & Ranchers United, an agriculture alliance based on Hawaii Island, it made sense to go and show support for Scott Enright; Hawaii’s Chair of the Department of Agriculture. It would have been remiss to pass up this opportunity to attend this annual convention full of Agriculture thought leaders. Due to the cost I had only planned on attending for one day but fate intervened and I Read More >

Food And Agriculture  |  Leave a comment  |  Email This Post
Tags: , , ,

PTAB Ruling Proves Medical Innovation Under Attack


There’s more evidence today that the IPR system needs to be fixed. PTAB ruled on Friday that under current rules, hedge fund managers are free to manipulate the system by shorting drug company stocks and then challenging their patents. Here’s what the panel said: “Profit is at the heart of nearly every patent and nearly every inter partes review. As such, an economic motive for challenging a patent claim does not itself raise abuse of Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

Warning: Don’t Let Bio-Euphoria Distract You from Being Disciplined


This piece by Allan L. Shaw was originally published in Life Science Leader. We currently in a period I call “bio-euphoria,” in which the biopharmaceutical industry is experiencing growth in almost every area from market performance to patient-focused legislation. In parallel to this positive momentum, there has also been a notable shift in management and operational strategy by Big Pharma companies in an attempt to keep evolving with the market. These companies are taking creative Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,